Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
By H. Kantarjian, A. Stein, N. Gökbuget, A. Fielding, A. Schuh, J. Ribera, A. Wei, H. Dombret, R. Foà, R. Bassan and 16 more. New England Journal of Medicine, 2017
1,744 citations recorded by the source corpus.
Background Blinatumomab, a bispecific monoclonal antibody construct that enables CD3‐positive T cells to recognize and eliminate CD19‐positive acute lymphoblastic leukemia (ALL) blasts, was approved for use in patients with relapsed or refractory B‐cell precursor ALL on the basis of single‐group trials that showed efficacy and manageable toxic effects. Methods In this multi‐institutional phase 3 trial, we randomly assigned adults with heavily pretreated B‐cell precursor ALL, in a 2:1 ratio, to receive either blinatumomab or standard‐of‐care chemotherapy. The primary end point was overall survival. Results Of the 405 patients who were randomly assigned to receive blinatumomab (271 patients) or chemotherapy (134 patients), 376 patients received at least one dose. Overall survival was significantly longer in the blinatumomab group than in the chemotherapy group. The median overall survival was 7.7 months in the blinatumomab group and 4.0 months in the chemotherapy group (hazard ratio for death with blinatumomab vs. chemotherapy, 0.71; 95% confidence interval [CI], 0.55 to 0.93; P=0.01). Remission rates within 12 weeks after treatment initiation were significantly higher in the blinatumomab group than in the chemotherapy group, both with respect to complete remission with full hematologic recovery (34% vs. 16%, P<0.001) and with respect to complete remission with full, partial, or incomplete hematologic recovery (44% vs. 25%, P<0.001). Treatment with blinatumomab resulted in a higher rate of event‐free survival than that with chemotherapy (6‐month estimates, 31% vs. 12%; hazard ratio for an event of relapse after achieving a complete remission with full, partial, or incomplete hematologic recovery, or death, 0.55; 95% CI, 0.43 to 0.71; P<0.001), as well as a longer median duration of remission (7.3 vs. 4.6 months). A total of 24% of the patients in each treatment group underwent allogeneic stem‐cell transplantation. Adverse events of grade 3 or higher were reported in 87% of the patients in the blinatumomab group and in 92% of the patients in the chemotherapy group. Conclusions Treatment with blinatumomab resulted in significantly longer overall survival than chemotherapy among adult patients with relapsed or refractory B‐cell precursor ALL. (Funded by Amgen; TOWER ClinicalTrials.gov number, NCT02013167.)
Subfields: Hematology, Oncology, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/ab561821bd6b88172b45f7529f756fcac7b101b8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Cytokine release syndrome (2018, background): “Some patients may harbor genetic variants that predispose them to developing HLH/MAS.”
- Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. (2018, background): “In a randomized phase 3 trial of patients with Philadelphia chromosome (Ph)-negative relapsed or refractory B-cell precursor ALL, 44% of 271 patients achieved hematologic CR with blinatumomab compared with 25% of 134 patients with standardof-care chemotherapy.(20) Based on a phase 2 pilot study in M”
- New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management (2017, methodology): “Additional diagnostic measures in this scenario included cerebrospinal fluid assessment with cytology, cell count, and virus-PCR analyses (for HSV1/2, HHV6, JC virus, and adenovirus) [8, 14].”
- Engineering strategies to overcome the current roadblocks in CAR T cell therapy (2019, background): “Transcription activator-like (TAL) effector nuclease (TALEN) technologies have also been used to knockout the TCR 232 , and TALEN-edited anti-CD19 CAR T cells have induced remissions in infants with B cell ALL, with no GVHD observed 233 .”